A photochemical flow reactor for large scale syntheses of aglain and rocaglate natural product analogues by Yueh, Han et al.
Boston University
OpenBU http://open.bu.edu
BU Open Access Articles BU Open Access Articles
2017-12-01
A photochemical flow reactor for
large scale syntheses of aglain and
rocaglate natural prod...
This work was made openly accessible by BU Faculty. Please share how this access benefits you.
Your story matters.
Version Accepted manuscript
Citation (published version): Han Yueh, Qiwen Gao, John A Porco, Aaron B Beeler. 2017. "A
photochemical flow reactor for large scale syntheses of aglain and
rocaglate natural product analogues." Bioorganic & Medicinal
Chemistry, Volume 25, Issue 23, pp. 6197 - 6202 (6).
https://doi.org/10.1016/j.bmc.2017.06.010
https://hdl.handle.net/2144/32940
Boston University
A Photochemical Flow Reactor for Large Scale Syntheses of 
Aglain and Rocaglate Natural Product Analogs
Han Yueh, Qiwen Gao, John A. Porco Jr., and Aaron B. Beeler
Department of Chemistry and Center for Molecular Discovery (BU-CMD), Boston University, 590 
Commonwealth Avenue, Boston, Massachusetts 02215
Abstract
Herein, we report the development of continuous flow photoreactors for large scale ESIPT-
mediated [3+2]-photocycloaddition of 2-(p-methoxyphenyl)-3-hydroxyflavone and cinnamate- 
derived dipolarophiles. These reactors can be efficiently numbered up to increase throughput two 
orders of magnitude greater than the corresponding batch reactions.
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1. Introduction
Rocaglates are a class of structurally complex secondary metabolites isolated from plants of 
the Aglaia genus [1-3]. Over 100 rocaglates have been isolated or synthesized, all sharing 
the cyclopenta[b]benzofuran core structure (Figure 1). The naturally occurring family 
members rocaglamide (1), rocaglaol (2), silvestrol (3), and the synthetic analogue RHT (4) 
possess potent cytotoxicity for a number of cancer cell lines [4-8]. Much of the anticancer 
activity of these compounds is believed to be derived from translation suppression through 
inhibition of the RNA helicase eIF4A. However, there have been a number of new and 
potentially important biological activities reported for the natural products and analogues. 
Methyl rocaglate (4) was found to be a specific inhibitor of TNFα-R or PMA-induced NF-
κB activity in T cell lines [4,5][9-13] and rocaglamide was recently reported to inhibit 
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cancer cell migration through Rho GTPase inhibition [14]. In a collaboration with Kramnik 
and co-workers, we found that the synthetic rocaglate derivatives (3 and 4) synergized with 
low concentrations of IFNγ in primary macrophages to stimulate expression of some IFN-
inducible genes, including a key regulatory factor, Irf1, which activates autophagy [15].
It is clear that the rocaglates have a number of unique biological activities that could lead to 
novel therapeutics. However, the chemical synthesis of rocaglate natural products and 
analogues has proven highly challenging [16-19]. The common approach leverages an 
excited-state intramolecular proton transfer (ESIPT)-mediated [3+2]-photocycloaddition to 
generate aglains (7) from 3-hydroxyflavone derivatives (5) and dipolarophiles (6) which was 
developed by the Porco laboratory (Scheme 1) [19][20]. Subsequent α-ketol rearrangement 
and hydroxyl-directed reduction affords the rocaglate skeleton (8) [21-25].
While this synthetic approach has been widely utilized, there has remained significant 
challenges related to practicality and scalability of the photochemical cycloaddition. Thus, 
synthesis of sufficient material to support medicinal chemistry studies of rocaglate analogues 
in vitro and in vivo has been a significant hurdle for development of this class of molecule. 
Herein, we report a numbering up approach for developing a multigram scale continuous 
flow reactor for ESIPT [3+2]-photocycloaddition.
2. Results and Discussion
The ESIPT [3+2]-photocycloaddition of 3-hydroxyflavone (9) and methyl trans-cinnamate 
(10) to obtain aglain (11) is typically carried out in batch, but is difficult to scale due to long 
irradiation times (typically 12 hours), low temperature (0 °C), and high dilution required (30 
mM). The typical isolated yield of aglain (11) is 40-50% affording on average <150 mg per 
reaction (Scheme 2a)[21]. In 2012, Tremblay and coworkers reported the use of a 
recirculating flow reactor for synthesis of methyl rocaglate and related derivatives (Scheme 
2c). This three-step sequence (photocycloaddition, α-ketol rearrangement, and hydroxyl-
directed reduction) was initiated with 3-hydroxyflavone derivative (11) and methyl trans-
cinnamate and gave an overall 20 % yield of the methyl rocaglate derivative (13) on a 3 g 
scale [26]. The synthesis of aza-rocaglates via ESIPT [3+2]-photocycloaddition was also 
recently reported using a recirculating flow device [27] wherein the aza-aglain derivative 
(15) was obtained in 46 % over nine hours of irradiation on a 500 mg scale. However, these 
methods remain limited in terms of scale and throughput [28]. To enable synthesis and 
medicinal chemistry programs related to the rocaglate scaffolds and to address the 
challenges of this reaction, we considered a continuous-flow approach which has been 
demonstrated to be highly beneficial for large scale synthesis of active pharmaceutical 
ingredients, natural products, and polymers have been reported [29-32]. In particular, 
photochemical reactions performed in a continuous-flow can be significantly more efficient 
than the corresponding batch reactions due to better light penetration, resulting in reduced 
reaction times, cleaner reactions, and greater scalability [33-39].
2.1 Optimization of ESIPT [3+2]-photocycloaddition in flow
While there have been significant advances in developing flow reactors for large scale 
photochemical reactions [40-42], there are still few available options which could be applied 
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to challenging reactions requiring low temperatures and are simple, affordable, and modular. 
We designed and built a novel flow photoreactor that would enable UV irradiation >300 nm 
while maintaining a low temperature for the photocycloaddition (Figure 2 A). The reactor 
utilizes a 150 W metal-halide lamp (>300 nm) which is placed in the center of a reactor 
containing wrapped FEP tubing. The inner chamber of the reactor is cooled by recirculation 
of glycol. We built the first flow reactor (Reactor A) using 1/16″ OD FEP tubing resulting 
in 3.5 mL reactor volume.
We began optimization of the reaction using 3-hydroxyflavone 9 [26] and methyl cinnamate 
10. Initial reactions revealed that under typical conditions (30 mM) full conversion was 
observed with only 15-minute residence time, compared to 9-hour reaction times required 
for the corresponding batch reaction (Table 1, entries 1 and 2). Increasing the concentration 
to 60 mM did not affect the reaction and we obtained an increased isolated yield (Table 1, 
entry 3). In order to maximize the potential throughput and minimize solvent waste, we 
increased the concentration to 120 mM at which point a longer 30-minute residence time 
was required for full conversion (Table 1, entry 4). Although isolated yields for the flow 
reactions were slightly lower than the batch reaction these initial efforts resulted in nearly a 
20-fold increase in throughput.
Targeting a key intermediate for medicinal chemistry studies, we evaluated the potential for 
large-scale synthesis of the Weinreb amide-bearing aglain 17 derived from ESIPT [3+2]-
photocycloaddition with hydroxamate 16 [43]. Aglain 17 is the precursor to the rocaglate 
congener RHT, an important tool molecule for studying inhibition of eIF4A, and an 
intermediate in the synthesis of many analogues including furan 6. Photoreaction of 3-
hydroxyflavone 9 and 16 afforded 47 % yield after 9 hours irradiation in a batch reactor 
(Table 1, entry 5) while the flow reaction at 120 mM required 30-minute residence time 
affording a 36 % isolated yield (Table 1, entry 6).
To increase the throughput of the reaction, we envisioned a numbering up approach [44] 
wherein we would daisy-chain reactors rather than splitting the reaction stream into separate 
reactors. In this way, we would effectively increase the total reactor volume allowing for 
greater flow rate, and subsequent throughput (Figure 2, B and C). We initially combined two 
reactors (reactor A) which effectively doubled the reactor volume to 7 mL. Reaction of 
hydroxyflavone 9 and dipolarophile 16 afforded a comparable isolated yield and the reaction 
throughput was increased from 0.12g/h to 0.22 g/h. Using this system, we synthesized 890 
mg of aglain product 17 in only four hours (Table 2, entry 2). By redesigning the reactor to 
have a larger surface area, it was possible to increase the volume to 6 mL/reactor (reactor B). 
Using this design, both a single and double reactor afforded similar yield, significantly 
increasing the throughput to 0.6 g/h (Table 2, entries 3 & 4).
In order to further increase the reactor volume and throughput, we built a new reactor with 
1/8″ OD FEP, resulting in a total volume of 12.5 mL for each reactor (reactor C). We found 
that the impact of the longer path length was minimal and we could obtain similar isolated 
yields with only a slightly longer residence time of 35 minutes. Numbering up this larger 
reactor to three resulted in a total volume of 37.5 mL, thereby maintaining a 35% yield to 
realize a throughput of 1.16 g/h (Table 2, entry 5).
Yueh et al. Page 3
Bioorg Med Chem. Author manuscript; available in PMC 2018 December 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A large scale [3+2] photocycloaddition was performed using this latest design. 21.3 g of 3-
hydroxyflavone (9) and 124.3 g of dipolarophile (16) with a total solution volume of 670 mL 
took 10.5 hours with a flow rate of 1.07 mL/min to reach completion. A total of 12.1 grams 
of aglain 17 was obtained after purification.
2.2 Synthesis of rocaglate analogs in flow
To validate that this flow system would be generally useful for medicinal chemistry and the 
synthesis of an array of rocaglate analogues, we evaluated a number of diopolarophiles in 
the flow ESIPT [3+2]-photocycloaddition. As outlined in Table 43, multiple reaction 
partners were found to be successful using the system, generally providing moderate to good 
isolated yields and excellent throughput. With the triple reactor configuration, we observed 
an increase to 61% isolated yield for methyl cinnamate. Reaction with p-bromo ethyl 
cinnamate (19) afforded aglain 24 in 52% isolated yield and the corresponding Weinreb 
amide (20) was equally successful in the reaction (52%). Reaction with o-bromo and m-
bromo Weinreb amides (21, 22) afforded lower isolated yields of the corresponding aglains 
(26: 32% and 27: 38% respectively) but maintained excellent throughput. The electron rich 
p-methoxy Weinreb amide (23) afforded a good yield (47%) and throughput of the expected 
aglain (28).
3. Conclusion
We have developed a series of simple continuous flow photoreactors for carrying out the 
ESIPT [3+2]-photocycloaddition, generating aglain derivatives on unprecedented scale. We 
have demonstrated the reactors can be effectively numbered up to increase the reaction 
throughput without significant change in the overall reaction outcome. Using a triple reactor, 
we successfully synthesized 12.1 grams of the critical aglain 17 in 10.5 hours. The ability to 
carry out these challenging reactions on a large scale has significantly improved the 
prospects for advancing these highly interesting molecules through in vitro and in vivo 
medicinal chemistry programs.
4. Experimental
4.1 General information
Photoreactors were constructed with fluorinated ethylene propylene (FEP) tubing (1/16″ 
[OD] – 1/32″ [ID], and 1/8″ [OD] – 1/16″ [ID]). The light source was metal halide lamp 
(MHL 150 G12) purchased from Ushio America (Cypress, CA) with metal halide ballast 
(V90D7130K) purchased from Venture Lighting International (Twinsburg, Ohio). Solutions 
were flowed through the TPFE photoreactors with Harvard Apparatus (Holliston, MA) PHD 
Ultra syringe pumps or KD Scientific (Holliston, MA) LEGATO 200 syringe pumps.
4.2 General procedure of [3+2]-photocycloaddition
The solvent (70:30 chloroform:2,2,2-trifluoroethanol) for photoreactions was degassed with 
argon for 10 minutes prior to dissolution of the reaction substrates. A flask containing 3-
hydroxyflavone 9 and dipolarophile was evacuated under high vacuum for 30 minutes then 
charged with argon. The degassed solvent mixture was added to the flask to prepare the 
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solution in the desired concentration. The solution subsequent reaction solution was 
transferred to appropriate syringes and placed into the flow system. The crude material was 
collected and after the reaction was complete the solution was concentrated dry loaded onto 
Celite followed by chromatography (SiO2, hexanes/ethyl acetate/Et3N). From the 
chromatography column was collected a mixture of the major product with regioisomers and 
diastereomers still present. Subsequent trituration with ethyl acetate/hexanes solution or 
recrystallization from acetonitrile afforded pure aglain product as a single diastereomer.
Supplementary Material
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Figure 1. Biologically active rocaglate natural products and analogues
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Figure 2. 
Flow reactor A.
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Figure 3. 
Daisy-chained reactors.
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Scheme 1. ESIPT-mediated [3+2] photocycloaddition
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Scheme 2. 
Previous studies a) [3+2] photocycloaddition in batch, b) recirculating flow reactor, c) aza-
aglain synthesis using a recirculating flow reactor.
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Scheme 4. Large scale [3+2] –triple reactor C (37.5 mL)
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